Stefania Morganti, MD, PhD

Emerging MRD tests show promise in enhancing breast cancer treatment by improving risk stratification and clinical outcomes for patients.

Expert explores innovative strategies for managing early stage breast cancer, focusing on minimal residual disease and potential treatment adjustments.

Early-stage breast cancer patients face challenges with ctDNA detection, highlighting the need for clinical trials to improve outcomes and reduce recurrence risks.

Explore the advancements in minimal residual disease (MRD) assays, comparing tumor-informed and tumor-agnostic methods for enhanced cancer detection and treatment strategies.

Emerging research highlights the challenges and potential of ctDNA in managing minimal residual disease in breast cancer, paving the way for innovative treatment strategies.

Circulating tumor DNA (ctDNA) revolutionizes minimal residual disease detection, offering a less invasive, real-time method to monitor cancer and guide treatment.